2024
CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics
Blahova Z, Ikezawa S, Falkai P, Krystal J, Rangan T. CONNEX, a Phase III Randomized Trial Program Assessing Efficacy and Safety of Iclepertin in Schizophrenia: Recruitment and Baseline Characteristics. BJPsych Open 2024, 10: s72-s73. DOI: 10.1192/bjo.2024.230.Peer-Reviewed Original ResearchVirtual Reality Functional Capacity Assessment ToolComposite T-scoreSchizophrenia Cognition Rating ScaleSchizophrenia Consensus Cognitive BatteryCognitive impairmentGlycine transporter-1 inhibitorStable antipsychotic treatmentN-methyl-d-aspartate receptor signallingConsensus Cognitive BatteryCognitive remediation therapyIncrease synaptic levelsCognition Rating ScaleT-scoreDuration of illnessCo-agonist glycineAntipsychotic treatmentAntipsychotic medicationSchizophrenia treatmentCognitive batteryRemediation therapyCognitive symptomsTreatment researchSchizophreniaImprove cognitionPlacebo-controlled parallel-group trial
2011
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders
Carter CS, Barch DM, Bullmore E, Breiling J, Buchanan RW, Butler P, Cohen JD, Geyer M, Gollub R, Green MF, Jaeger J, Krystal JH, Moore H, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T. Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders. Biological Psychiatry 2011, 70: 7-12. PMID: 21529781, PMCID: PMC3116022, DOI: 10.1016/j.biopsych.2011.01.041.Peer-Reviewed Original ResearchConceptsCognitive Neuroscience Treatment ResearchTreatment researchCognitive neuroscienceTreatment developmentFunctional magnetic resonance imagingSchizophrenia (MATRICS) initiativeSchizophrenia IIPotential confoundsImpaired cognitionCognitionNeural systemsNeural activityPsychometric propertiesMental healthBrain functionTranscranial magnetic simulationNeuroscienceTreatment effectsSchizophreniaMulticenter phase IITranslational researchImproved animal modelsPragmatic issuesBiological psychiatryMagnetic resonance imaging
2008
Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting
Barch DM, Carter CS, Arnsten A, Buchanan RW, Cohen JD, Geyer M, Green MF, Krystal JH, Nuechterlein K, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Selecting Paradigms From Cognitive Neuroscience for Translation into Use in Clinical Trials: Proceedings of the Third CNTRICS Meeting. Schizophrenia Bulletin 2008, 35: 109-114. PMID: 19023126, PMCID: PMC2643950, DOI: 10.1093/schbul/sbn163.Peer-Reviewed Original ResearchConceptsFirst CNTRICS meetingCognitive neuroscienceCognitive Neuroscience Treatment ResearchPromising taskSchizophrenia (MATRICS) initiativeTreatment researchBroad domainsTaskSuch paradigmsNeuroscienceSpecific paradigmSpecific tasksRelevant paradigmConstructsParadigmLine surveyCognitionSpecial issueGoalNominationsDomainResearchInformationArticleTrialsIdentifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry 2008, 64: 4-10. PMID: 18466880, PMCID: PMC2577821, DOI: 10.1016/j.biopsych.2008.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsBiomedical ResearchBrainCognition DisordersCooperative BehaviorDrug IndustryHumansNational Institute of Mental Health (U.S.)Neuropsychological TestsResearch Support as TopicSchizophreniaSchizophrenic PsychologyUnited StatesUnited States Food and Drug AdministrationConceptsCognitive Neuroscience Treatment ResearchSchizophrenia (MATRICS) initiativeTreatment researchCognitive neuroscience fieldCNTRICS initiativeCognitive mechanismsCognitive constructsTreatment developmentNeuroscience fieldCognitive impairmentCognitionBasic animalSchizophreniaResearchFirst meetingImpairmentConstructsParadigmTranslational researchTranslation effortsNovel treatmentsOrganization
2005
Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia
Cho RY, Ford JM, Krystal JH, Laruelle M, Cuthbert B, Carter CS. Functional Neuroimaging and Electrophysiology Biomarkers for Clinical Trials for Cognition in Schizophrenia. Schizophrenia Bulletin 2005, 31: 865-869. PMID: 16166611, DOI: 10.1093/schbul/sbi050.Peer-Reviewed Original ResearchConceptsFunctional neuroimagingCognitive impairmentCognitive processesNeurobiological indicesTest-retest reliabilityCognitive functionTreatment researchDiscrepant findingsCognitionMental healthAdditional basic researchSchizophreniaNeuroimagingNovel pharmacotherapeuticsImpairmentParadigmResearchParticipantsBasic researchNIMHMatricFindingsRelative advantagesTrialsPerspective